61.59
price up icon0.95%   0.715
 
loading
전일 마감가:
$60.88
열려 있는:
$60.95
하루 거래량:
33,475
Relative Volume:
0.02
시가총액:
$8.85B
수익:
-
순이익/손실:
$-766.63M
주가수익비율:
-10.80
EPS:
-5.7051
순현금흐름:
$-712.55M
1주 성능:
+2.74%
1개월 성능:
+12.61%
6개월 성능:
+40.29%
1년 성능:
+96.99%
1일 변동 폭
Value
$60.95
$61.73
1주일 범위
Value
$58.51
$62.78
52주 변동 폭
Value
$28.09
$65.00

백스사이트 Stock (PCVX) Company Profile

Name
명칭
Vaxcyte Inc
Name
전화
650-837-0111
Name
주소
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Name
직원
507
Name
트위터
Name
다음 수익 날짜
2026-02-24
Name
최신 SEC 제출 서류
Name
PCVX's Discussions on Twitter

Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
PCVX icon
PCVX
Vaxcyte Inc
61.50 8.76B 0 -766.63M -712.55M -5.7051
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
436.05 110.97B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
750.33 79.17B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
800.13 49.73B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
321.19 42.98B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
310.52 34.37B 5.36B 287.73M 924.18M 2.5229

백스사이트 Stock (PCVX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2026-01-07 재확인 Needham Buy
2025-09-12 개시 Goldman Neutral
2025-04-22 개시 Cantor Fitzgerald Overweight
2024-12-20 개시 Goldman Buy
2023-12-07 개시 Mizuho Buy
2023-04-18 개시 TD Cowen Outperform
2023-01-03 재확인 Needham Buy
2022-12-15 개시 Guggenheim Buy
2022-11-17 개시 BTIG Research Buy
2021-12-29 재개 Jefferies Buy
2021-06-24 재개 Jefferies Buy
2020-07-07 개시 BofA Securities Buy
2020-07-07 개시 Cantor Fitzgerald Overweight
2020-07-07 개시 Needham Buy
모두보기

백스사이트 주식(PCVX)의 최신 뉴스

pulisher
Apr 12, 2026

PCVX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 12, 2026
pulisher
Apr 11, 2026

How Vaxcyte Inc. (PCVX) Affects Rotational Strategy Timing - Stock Traders Daily

Apr 11, 2026
pulisher
Apr 10, 2026

Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump? - Yahoo Finance

Apr 10, 2026
pulisher
Apr 10, 2026

What is the target price for Vaxcyte Inc stock2026 Momentum Check & AI Forecasted Entry/Exit Points - baoquankhu1.vn

Apr 10, 2026
pulisher
Apr 09, 2026

PCVX SEC FilingsVaxcyte, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 09, 2026
pulisher
Apr 09, 2026

Vaxcyte CAO Sells $180,000 in Company Stock - National Today

Apr 09, 2026
pulisher
Apr 08, 2026

Vaxcyte CAO Sells $180,000 in Stock - National Today

Apr 08, 2026
pulisher
Apr 08, 2026

Vaxcyte (PCVX) finance chief sells 3,000 shares after option exercise - Stock Titan

Apr 08, 2026
pulisher
Apr 08, 2026

Vaxcyte to Present at Annual Healthcare Conference - National Today

Apr 08, 2026
pulisher
Apr 08, 2026

Vaxcyte Inc stock: Why its pneumococcal vaccine pipeline draws investor focus - AD HOC NEWS

Apr 08, 2026
pulisher
Apr 08, 2026

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Sahm

Apr 08, 2026
pulisher
Apr 07, 2026

Elvia Cowan registers 3,000-share sale (PCVX) after option exercise - Stock Titan

Apr 07, 2026
pulisher
Apr 06, 2026

Vaxcyte (PCVX) Stock Analysis Report | Financials & Insights - Benzinga Japan

Apr 06, 2026
pulisher
Apr 05, 2026

Aberdeen Group plc Increases Holdings in Vaxcyte, Inc. $PCVX - MarketBeat

Apr 05, 2026
pulisher
Apr 04, 2026

PCVX.O Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026
pulisher
Apr 04, 2026

PCVX Should I Buy - Intellectia AI

Apr 04, 2026
pulisher
Apr 03, 2026

Insider Sell Alert: Jim Wassil Sells 2,250 Shares of Vaxcyte Inc (PCVX) - GuruFocus

Apr 03, 2026
pulisher
Apr 03, 2026

Vaxcyte (PCVX) COO sells 2,250 shares in planned Rule 10b5-1 trades - Stock Titan

Apr 03, 2026
pulisher
Apr 01, 2026

James Wassil sells 7,395 PCVX shares (NASDAQ: PCVX) - Stock Titan

Apr 01, 2026
pulisher
Apr 01, 2026

Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 01, 2026
pulisher
Apr 01, 2026

Aug Ideas: Is now the right time to enter Vaxcyte Inc2026 Short Interest & Trade Opportunity Analysis Reports - baoquankhu1.vn

Apr 01, 2026
pulisher
Mar 31, 2026

(PCVX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Mar 31, 2026
pulisher
Mar 31, 2026

Vaxcyte joins elite club of stocks with RS ratings over 90 - msn.com

Mar 31, 2026
pulisher
Mar 30, 2026

Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener

Mar 30, 2026
pulisher
Mar 30, 2026

Certain Pre-funded warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com

Mar 30, 2026
pulisher
Mar 30, 2026

Certain Restricted Stock Units of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com

Mar 30, 2026
pulisher
Mar 30, 2026

Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener

Mar 30, 2026
pulisher
Mar 30, 2026

Should Vaxcyte’s (PCVX) Fully Enrolled VAX-31 Phase 3 Trials Prompt a Portfolio Reassessment? - simplywall.st

Mar 30, 2026
pulisher
Mar 27, 2026

Vanguard disaggregates holdings; PCVX ownership shown as 0 (PCVX) - stocktitan.net

Mar 27, 2026
pulisher
Mar 26, 2026

Portfolio Update: Can Vaxcyte Inc continue delivering strong returns2026 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn

Mar 26, 2026
pulisher
Mar 26, 2026

Assenagon Asset Management S.A. Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat

Mar 26, 2026
pulisher
Mar 25, 2026

Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO - Law360

Mar 25, 2026
pulisher
Mar 24, 2026

Vaxcyte completes enrollment in two Phase 3 trials for VAX-31 - Investing.com Canada

Mar 24, 2026
pulisher
Mar 23, 2026

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - Investing News Network

Mar 23, 2026
pulisher
Mar 23, 2026

Vaxcyte (PCVX) Completes Enrollment for Key Phase 3 Trials - GuruFocus

Mar 23, 2026
pulisher
Mar 21, 2026

Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative - simplywall.st

Mar 21, 2026
pulisher
Mar 20, 2026

Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet - simplywall.st

Mar 20, 2026
pulisher
Mar 20, 2026

Responsive Playbooks and the PCVX Inflection - Stock Traders Daily

Mar 20, 2026
pulisher
Mar 20, 2026

Vaxcyte Announces Significant Development of First-of-Its-Kind PCV31 - Drug Topics

Mar 20, 2026
pulisher
Mar 20, 2026

PCVX PE Ratio & Valuation, Is PCVX Overvalued - Intellectia AI

Mar 20, 2026
pulisher
Mar 20, 2026

JPMorgan Chase & Co. Acquires 366,266 Shares of Vaxcyte, Inc. $PCVX - MarketBeat

Mar 20, 2026
pulisher
Mar 19, 2026

Vaxcyte, Inc.: Fundamental Analysis and Financial Ratings | 1PCVX | US92243G1085 - marketscreener.com

Mar 19, 2026
pulisher
Mar 19, 2026

Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet - Investing.com Australia

Mar 19, 2026
pulisher
Mar 19, 2026

Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCVX) - GuruFocus

Mar 19, 2026
pulisher
Mar 19, 2026

Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCV - GuruFocus

Mar 19, 2026
pulisher
Mar 18, 2026

Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet By Investing.com - Investing.com South Africa

Mar 18, 2026
pulisher
Mar 18, 2026

Vaxcyte (PCVX) Advances VAX-31 Vaccine with Positive Study Resul - GuruFocus

Mar 18, 2026

백스사이트 (PCVX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

백스사이트 주식 (PCVX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Cowan Elvia
SVP, Finance & CAO
Apr 07 '26
Sale
60.00
3,000
180,000
28,975
$28.45
price up icon 0.62%
$47.98
price down icon 0.89%
$95.98
price up icon 0.65%
$129.95
price up icon 34.66%
$155.43
price down icon 3.38%
ONC ONC
$310.52
price up icon 0.28%
자본화:     |  볼륨(24시간):